Korea Investment Partners has led a EUR17.5 million Series B2 financing round in PDC*line Pharma, a clinical stage biotech company developing a new class of off-the-shelf lung cancer vaccine.
Less than two years after its EUR20M B1 round of fundraising, announced in January 2020, PDC*line Pharma has attracted new investors and secured a further capital increase of EUR11.8 million. In addition, the company has received a EUR5.7 million grant in repayable aid from the Walloon Region of Belgium, which has backed the company since its arrival in 2016. The company will therefore have raised a total of EUR37.5 million in this series B round.
